Search alternatives:
point decrease » point increase (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a point » _ point (Expand Search), 5 point (Expand Search), _ points (Expand Search)
50 ng » 50 mg (Expand Search), 10 ng (Expand Search), 5 ng (Expand Search)
point decrease » point increase (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a point » _ point (Expand Search), 5 point (Expand Search), _ points (Expand Search)
50 ng » 50 mg (Expand Search), 10 ng (Expand Search), 5 ng (Expand Search)
-
121
-
122
Behavior of split<sup><50cM</sup> <i>ClvR</i> V2 with linkage.
Published 2021“…<p>Incorporating linkage into split <i>ClvR</i> (split<sup><50cM</sup> <i>ClvR</i> V2) results in a graded increase in drive strength, and duration of <i>Rescue</i>/Cargo/gRNAs at high frequency, as the degree of linkage increases (map distance decreases). …”
-
123
-
124
-
125
AMPs are increased in lesional HS, but DCD and other sweat-gland associated proteins are decreased.
Published 2019“…<p>(A) Volcano plot showing increased or decreased genes in HS. …”
-
126
-
127
-
128
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
Published 2025“…<p>(A) Ki-67 expression in parathyroid glands of rats with CKD-induced sHPT treated with Cinacalcet either early in the inactive light phase (<i>Cina1</i>; N = 10) or early in the active dark phase (<i>Cina2</i>; N = 9) compared to untreated rats with sHPT investigated at similar time points (<i>PNX1</i>; N = 7 and <i>PNX2</i>; N = 7, respective) and to normal rats investigated at similar time points (<i>ctrl1</i>; N = 9 and <i>ctrl2</i>; N = 7, respective). …”
-
129
-
130
-
131
-
132
-
133
-
134
-
135
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
136
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
137
-
138
-
139
-
140